India, Aug. 21 -- Initiator Pharma A/S (INIT.AS), a clinical-stage life sciences company, released on Thursday second quarter financial results and noted a wider loss as expenses climbed with higher clinical costs.
The company specializes in developing drugs that target untreatable diseases of the central and peripheral nervous systems.
Q2 Financial Results:
The company's operating EBITDA loss expanded to DKK 9.49 million in the second quarter of 2026, nearly three times of the DKK 3.84 million reported in the same period of 2025. The increased loss was associated with higher costs of clinical trials for its lead drug candidate, Pudafensine.
Earnings per share resulted in a loss of DKK 0.14 per share, compared to DKK 0.07 per share in t...